REGENXBIO Price to Sales Ratio 2014-2022 | RGNX

Historical PS ratio values for REGENXBIO (RGNX) over the last 10 years. The current P/S ratio for REGENXBIO as of May 27, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
REGENXBIO P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-05-27 21.78 2.01
2022-03-31 33.19 $10.84 3.06
2021-12-31 32.70 $10.77 3.04
2021-09-30 41.92 $2.27 18.49
2021-06-30 38.85 $4.09 9.50
2021-03-31 34.11 $4.02 8.49
2020-12-31 45.36 $4.04 11.23
2020-09-30 27.52 $3.79 7.27
2020-06-30 36.83 $1.64 22.45
2020-03-31 32.38 $1.41 22.96
2019-12-31 40.97 $0.96 42.71
2019-09-30 35.60 $1.75 20.33
2019-06-30 51.37 $1.51 34.06
2019-03-31 57.31 $2.43 23.60
2018-12-31 41.95 $6.27 6.69
2018-09-30 75.50 $5.22 14.46
2018-06-30 71.75 $5.11 14.04
2018-03-31 29.85 $4.19 7.13
2017-12-31 33.25 $0.34 97.07
2017-09-30 32.95 $0.34 97.35
2017-06-30 19.75 $0.30 65.83
2017-03-31 19.30 $0.18 109.60
2016-12-31 18.55 $0.17 106.63
2016-09-30 14.01 $0.59 23.59
2016-06-30 8.00 $0.83 9.68
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.939B $0.470B
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00